Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.3Wikipedia text CC BY-SA 4.0
Beam Therapeutics Inc. is an American biotechnology company conducting research in the field of gene therapies and genome editing. The company is headquartered in Cambridge, Massachusetts. In the development of therapies, the company relies on CRISPR base editing and prime editing, whereby single nucleotides in a DNA sequence can be enzymatically modified without producing double-strand breaks.3
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Out of $139.7M in revenue.7 The company lost money this year.
Financial statements
Revenue8910117$139.7M in 2025+776250% since 2019Operating income8910117-$383.7M in 2025+411% since 2019Net income8910117-$80.0M in 2025+2% since 2019
Revenue1213$490.0K in Q2 FY2026−98% since Q1 FY2026Operating income1213-$126.6M in Q2 FY2026+18% since Q1 FY2026Net income1213-$122.7M in Q2 FY2026+30% since Q1 FY2026
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
Period ending
2025-12-31
2024-12-31
2023-12-31
License and collaboration revenue
$139.7M
$63.5M
$377.7M
Research and development
$409.6M
$367.6M
$437.4M
General and administrative
$113.8M
$111.5M
$116.8M
Total operating expenses
$523.4M
$479.1M
$554.2M
Loss from operations
-$383.7M
-$415.6M
-$176.5M
Change in fair value of derivative liabilities
$700.0K
$2.3M
$7.5M
Change in fair value of non-controlling equity investments
$3.9M
-$14.1M
-$18.6M
Change in fair value of contingent consideration liabilities
$180.0K
$1.6M
$9.7M
Gain on sale of equity method investment
$255.1M
Interest and other income (expense), net
$43.7M
$49.1M
$46.7M
Total other income (expense)
$303.7M
$38.9M
$45.3M
Net loss before income taxes
-$80.0M
-$376.7M
-$131.2M
Provision for income taxes
$0
-$39.0K
-$1.4M
Net loss
-$80.0M
-$376.7M
-$132.5M
Unrealized gain (loss) on marketable securities
$432.0K
$75.0K
$3.0M
Comprehensive loss
-$79.6M
-$376.7M
-$129.5M
Net loss per common share, basic
-$0.81
-$4.58
-$1.72
Net loss per common share, diluted
-$0.81
-$4.58
-$1.72
Weighted - average common shares outstanding, basic
98.9M shares
82.3M shares
77.2M shares
Weighted - average common shares outstanding, diluted
98.9M shares
82.3M shares
77.2M shares
No quarter-by-quarter statement was filed.
Total assets148910117$1.5B in 2025+849% since 2019Total liabilities148910117$242.8M in 2025+340% since 2019Shareholders’ equity910117$1.2B in 2025Cash8910117$294.9M in 2025+692% since 2019
Total assets1213$1.4B in Q2 FY2026−6% since Q1 FY2025Total liabilities1213$318.9M in Q2 FY2026+31% since Q1 FY2025Shareholders’ equity1213$1.1B in Q2 FY2026−14% since Q1 FY2025Cash1213$219.8M in Q2 FY2026−25% since Q1 FY2025Long-term debt1213$100.3M in Q2 FY2026+0% since Q1 FY2026
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
Period ending
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Cash and cash equivalents
$294.9M
$282.0M
$435.9M
Marketable securities
$950.3M
$568.8M
Prepaid expenses and other current assets
$23.5M
$27.4M
Total current assets
$1.3B
$878.1M
Property and equipment, net
$104.5M
$111.4M
Restricted cash
$6.7M
$8.1M
$8.7M
Operating lease right-of-use assets
$100.7M
$104.9M
Other assets
$634.0K
$1.3M
Total assets
$1.5B
$1.1B
Accounts payable
$10.2M
$3.9M
Accrued expenses and other current liabilities
$55.3M
$47.5M
Current portion of derivative liabilities
$7.7M
$8.4M
Current portion of deferred revenue
$6.7M
$108.9M
Current portion of lease liability
$14.4M
$13.5M
Current portion of contingent consideration liabilities
$2.7M
Total current liabilities
$96.9M
$182.1M
Long-term lease liability
$139.8M
$148.0M
Long-term portion of contingent consideration liabilities
$6.0M
$1.1M
Long-term portion of deferred revenue
$0
$33.2M
Long-term portion of derivative liabilities
$0
$5.4M
Other liabilities
$173.0K
$504.0K
Total liabilities
$242.8M
$370.3M
Common stock, $0.01 par value; 250,000,000 shares authorized, 101,748,962 and 83,633,069 issued and outstanding at December 31, 2025 and December 31, 2024, respectively
$1.0M
$836.0K
Additional paid-in capital
$2.9B
$2.3B
Accumulated other comprehensive (loss) income
$1.1M
$679.0K
Accumulated deficit
-$1.6B
-$1.6B
Total stockholders' equity
$1.2B
$733.5M
$981.3M
$733.5M
Total liabilities and stockholders' equity
$1.5B
$1.1B
Preferred stock, par or stated value per share
$0.01
$0.01
Preferred stock, shares authorized
25.0M shares
25.0M shares
Preferred stock, shares issued
0 shares
0 shares
Preferred stock, shares outstanding
0 shares
0 shares
Common stock, par or stated value per share
$0.01
$0.01
Common stock, shares authorized
250.0M shares
250.0M shares
Common stock, shares issued
101.7M shares
83.6M shares
Common stock, shares outstanding
101.7M shares
83.6M shares
Period ending
2025-12-31
2024-12-31
2023-12-31
2022-12-31
Cash and cash equivalents
$294.9M
$282.0M
$435.9M
Marketable securities
$950.3M
$568.8M
Prepaid expenses and other current assets
$23.5M
$27.4M
Total current assets
$1.3B
$878.1M
Property and equipment, net
$104.5M
$111.4M
Restricted cash
$6.7M
$8.1M
$8.7M
Operating lease right-of-use assets
$100.7M
$104.9M
Other assets
$634.0K
$1.3M
Total assets
$1.5B
$1.1B
Accounts payable
$10.2M
$3.9M
Accrued expenses and other current liabilities
$55.3M
$47.5M
Current portion of derivative liabilities
$7.7M
$8.4M
Current portion of deferred revenue
$6.7M
$108.9M
Current portion of lease liability
$14.4M
$13.5M
Current portion of contingent consideration liabilities
$2.7M
Total current liabilities
$96.9M
$182.1M
Long-term lease liability
$139.8M
$148.0M
Long-term portion of contingent consideration liabilities
$6.0M
$1.1M
Long-term portion of deferred revenue
$0
$33.2M
Long-term portion of derivative liabilities
$0
$5.4M
Other liabilities
$173.0K
$504.0K
Total liabilities
$242.8M
$370.3M
Common stock, $0.01 par value; 250,000,000 shares authorized, 101,748,962 and 83,633,069 issued and outstanding at December 31, 2025 and December 31, 2024, respectively
$1.0M
$836.0K
Additional paid-in capital
$2.9B
$2.3B
Accumulated other comprehensive (loss) income
$1.1M
$679.0K
Accumulated deficit
-$1.6B
-$1.6B
Total stockholders' equity
$1.2B
$733.5M
$981.3M
$733.5M
Total liabilities and stockholders' equity
$1.5B
$1.1B
Preferred stock, par or stated value per share
$0.01
$0.01
Preferred stock, shares authorized
25.0M shares
25.0M shares
Preferred stock, shares issued
0 shares
0 shares
Preferred stock, shares outstanding
0 shares
0 shares
Common stock, par or stated value per share
$0.01
$0.01
Common stock, shares authorized
250.0M shares
250.0M shares
Common stock, shares issued
101.7M shares
83.6M shares
Common stock, shares outstanding
101.7M shares
83.6M shares
Cash from operations8910117-$345.1M in 2025+379% since 2019Capital spending8910117$14.9M in 2025+19% since 2019Free cash flow8910117-$360.0M in 2025+326% since 2019
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
Period ending
2025-12-31
2024-12-31
2023-12-31
Net loss
-$80.0M
-$376.7M
-$132.5M
Depreciation and amortization
$22.3M
$21.9M
$20.0M
Amortization of investment discount (premiums)
-$16.0M
-$22.8M
-$29.7M
In-process research and development charge
$14.5M
$0
$0
Stock-based compensation expense
$94.2M
$120.7M
$98.6M
Change in operating lease right-of-use assets
$10.4M
$9.7M
$9.5M
Change in fair value of derivative liabilities
-$700.0K
-$2.3M
-$7.5M
Change in fair value of contingent consideration liabilities
-$180.0K
-$1.6M
-$9.7M
Change in fair value of non-controlling equity investments
-$3.9M
$14.1M
$18.6M
Realized loss (gain) on sale of marketable securities
$399.0K
$0
$0
Gain on sale of equity method investment
-$255.1M
$0
$0
Prepaid expenses and other current assets
$4.5M
-$5.3M
-$6.6M
Accounts payable
$6.0M
$1.8M
-$7.6M
Accrued expenses and other liabilities
$7.7M
-$57.7M
$67.7M
Operating lease liabilities
-$13.5M
-$13.0M
-$10.2M
Deferred revenue
-$135.4M
-$36.5M
-$159.6M
Other long-term liabilities
-$330.0K
$473.0K
-$194.0K
Net cash provided by (used in) operating activities
-$345.1M
-$347.2M
-$149.2M
Purchases of property and equipment
-$14.9M
-$8.9M
-$33.7M
Purchases of marketable securities
-$1.2B
-$486.4M
-$984.3M
Maturities of marketable securities
$842.5M
$680.4M
$1.1B
Proceeds from sale of marketable securities
$5.7M
$0
$0
Cash paid for acquisition, net
-$78.0K
$0
$0
Proceeds from sale of equity method investment
$255.1M
$0
$0
Net cash provided by (used in) investing activities
-$121.4M
$185.0M
$71.8M
Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs
$470.5M
$0
$235.9M
Proceeds from issuances of stock under ESPP
$2.8M
$2.6M
$3.0M
Equipment financings, net
$0
-$485.0K
-$2.3M
Proceeds from exercise of stock options
$4.8M
$5.6M
$6.1M
Proceeds from private stock issuance
$0
$0
$33.6M
Net cash provided by (used in) financing activities
$478.0M
$7.7M
$276.4M
Net change in cash, cash equivalents and restricted cash
$11.5M
-$154.5M
$199.1M
Cash paid for interest
$0
$32.0K
$160.0K
Property and equipment additions in accounts payable and accrued expenses
$1.3M
$834.0K
$1.4M
Operating lease liabilities arising from obtaining right-of-use assets
$6.2M
-$1.6M
$3.9M
Contingent consideration liabilities assumed in acquisition
$7.7M
$0
$0
Fair value of equity instruments issued in connection with acquisition
Beam Therapeutics sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Beam Therapeutics
ARK Investment Management LLCFiled SCHEDULE 13G/A on Beam Therapeutics, latest Aug 14, 2026 (7 filings since Feb 9, 2022)
Redmile Group, LLCFiled SC 13G/A on Beam Therapeutics, latest Feb 14, 2022
Beam TherapeuticsCambridge, Massachusetts
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Beam Therapeutics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
We have leased approximately 130,258 square feet of office and laboratory space in Cambridge, Massachusetts under a lease that expires in 2034. Additionally, we entered into a lease agreement with Alexandria Real Estate Equities, Inc. pursuant to which we built
a 100,000 square foot manufacturing facility in Research Triangle Park, North Carolina intended to support a broad range of clinical programs, which lease expires in 2037. We believe that our facilities are sufficient to meet our current needs and that suitable additional space will be available as and when needed.
Founded in 2017, the company traces its origins to the Broad Institute of the Massachusetts Institute of Technology and Harvard University. Co-founders include David R. Liu and Feng Zhang. Prior to its IPO, the company raised nearly $1 billion in venture capital from investors. In a February 2020 IPO, the company raised $180 million.
In January 2022, Pfizer and Beam Therapeutics announced a collaboration to develop therapies for rare diseases using CRISPR.
In 2026 clinical trial results were published on Beam's investigational medicine, ristoglogene autogetemcel, a CRISPR-based gene therapy for treatment of sickle cell disease.
Feb 25, 2025Reported quarterly or annual results46
Drug trials and FDA: coming up
Dec 2026Phase 1/2 trial readout expected Phase 1/2 trial of BEAM-201 in Lymphoblastic Lymphoma: primary completion expected Dec 2026 (ClinicalTrials.gov NCT05885464).47
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). Trials from ClinicalTrials.gov, as the sponsor registered them (expected dates are the sponsor's own and often move); approvals and advisory committee meetings from the FDA. The FDA does not publish its decision (PDUFA) dates. The full markets calendar
Filings
362 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 50 major events, 171 insider forms, 50 large holders, 71 other. The latest 20:
97 open-market trades by officers, directors and large owners since October 2021: 0 buys and 97 sales. Grants, option exercises and gifts are left out.
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
From the cover page of the 10-K filed Feb 24, 2026 (Section 12(b) of the Exchange Act).15
Risk factors and legal proceedings
The risks Beam Therapeutics names in Item 1A of its 10-K filed Feb 24, 2026: 73 risks under these headings, as written.15
Risks related to our financial position and need for additional capital
We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.
We will need substantial additional funding. If we are unable to raise capital when needed, we would be forced to delay, reduce, or eliminate our research and product development programs or future commercialization efforts.
Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates we may develop.
Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
We have never generated revenue from product sales and may never become profitable.
Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
The terms of our financing agreement with Sixth Street Lending Partners and our indebtedness could adversely affect our operations and limit our ability to plan for or respond to changes in our business. If we are unable to comply with restrictions in the financing agreement, the repayment of our existing indebtedness could be accelerated.
Risks related to discovery, development, and commercialization
Base editing is a novel technology that has only recently been clinically validated for human therapeutic use. The approaches we are taking to discover and develop novel therapeutics are early in their development and may never lead to marketable products.
We are early in our development efforts. Our product candidates are still in preclinical or clinical development and we have not, and may never, commercialize a product candidate. If we are unable to advance our product candidates through clinical development, obtain regulatory approval and ultimately commercialize our product candidates, or experience significant delays in doing so, our business will be materially harmed.
If any of the product candidates we may develop, or the delivery modalities we rely on to administer them, cause serious adverse events, undesirable side effects, or unexpected characteristics, such events, side effects or characteristics could delay or prevent regulatory approval of the product candidates, limit the commercial potential, or result in significant negative consequences following any potential marketing approval.
The other 63 risks
We have only recently begun testing our proposed delivery modalities and product candidates in clinical trials and any favorable preclinical results, or initial clinical results, are not necessarily predictive of results that may be observed in later clinical trials.
If we experience delays or difficulties in the enrollment or treatment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.
If clinical trials of any product candidates we identify and develop fail to demonstrate safety, purity and potency to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of such product candidates.
We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success.
We are conducting clinical trials at sites outside the United States. The FDA may not accept data from trials conducted in such locations, and the conduct of trials outside the United States could subject us to additional delays and expense.
Even if we complete the necessary clinical trials, we cannot predict when, or if, we will obtain regulatory approval to commercialize a product candidate we develop in the United States or any other jurisdiction, and any such approval may be for a narrower indication than we seek.
Even if any product candidates we may develop receive marketing approval, they may fail to achieve the degree of market acceptance by physicians, patients, healthcare payors, and others in the medical community necessary for commercial success.
If, in the future, we are unable to establish sales and marketing capabilities or enter into agreements with third parties to sell and market any product candidates we may develop, we may not be successful in commercializing those product candidates if and when they are approved.
We face significant competition in an environment of rapid technological change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.
Adverse public perception of genetic medicines, and gene editing and base editing in particular, may negatively impact regulatory approval of, and/or demand for, our potential products.
Even if we are able to commercialize any product candidates, such products may become subject to unfavorable pricing regulations, third-party reimbursement practices, or healthcare reform initiatives, which would harm our business.
Due to the novel nature of our technology and the potential for any product candidates we may develop to offer therapeutic benefit in a single administration or limited number of administrations, we face uncertainty related to pricing and reimbursement for these product candidates.
If the market opportunities for any product candidates we may develop are smaller than we believe they are, our potential revenues may be adversely affected, and our business may suffer. Because the target patient populations for many of the product candidates we may develop are small, we must be able to successfully identify patients and achieve a significant market share to maintain profitability and growth.
If we are unable to successfully identify patients who are likely to benefit from therapy with any product candidates we develop, or experience significant delays in doing so, we may not realize the full commercial potential of any medicines we may develop.
Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any medicines that we may develop.
We are subject to regulatory and operational risks associated with our internal manufacturing facility.
If we or any CMOs and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
Genetic medicines are novel, and any product candidates we develop may be complex and difficult to manufacture. We could experience delays in satisfying regulatory authorities or production problems that result in delays in our development or commercialization programs, limit the supply of our product candidates we may develop, or otherwise harm our business.
Risks related to our relationships with third parties
We rely on and expect to continue to rely on third parties to manufacture components of our product candidates we may develop, conduct our clinical trials and some aspects of our research and preclinical testing, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research, or testing.
As our drug development pipeline increases and matures, the increased demand for clinical supplies from our facilities and third parties may impact our ability to operate. We will require increased capacity across our entire supply chain. Furthermore, we rely on many service providers, including those that provide manufacturing or testing services, all of whom have inherent risks in their operations that may adversely impact our operations.
We have and may in the future enter into collaborations with third parties for the research, development, and commercialization of certain of the product candidates we develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.
If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.
If we are not able to establish collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.
Risks related to our intellectual property
If we are unable to obtain and maintain patent and other intellectual property protection for any product candidates we develop and for our platform technologies, or if the scope of the patent and other intellectual property protection obtained is not sufficiently broad, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize any product candidates we may develop, and our platform technologies may be adversely affected.
Our rights to develop and commercialize our base editing platform technology and product candidates are subject, in part, to the terms and conditions of licenses granted to us by others.
Our owned and in-licensed patents and patent applications may not provide sufficient protection of our platform technologies, our product candidates and our future product candidates or result in any competitive advantage.
Our owned patents and patent applications and in-licensed patents and patent applications and other intellectual property may be subject to priority disputes or to inventorship disputes and similar proceedings. If we or our licensors are unsuccessful in any of these proceedings, we may be required to obtain licenses from third parties, which may not be available on commercially reasonable terms or at all, or to cease the development, manufacture, and commercialization of one or more of the product candidates we may develop, which could have a material adverse impact on our business.
We have limited foreign intellectual property rights and may not be able to protect our intellectual property and proprietary rights throughout the world.
If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.
We may not be successful in acquiring or in-licensing necessary rights to key technologies or any product candidates we may develop.
The intellectual property landscape around gene editing technology, including base editing and delivery technology, is highly dynamic, and third parties may initiate legal proceedings alleging that we are infringing, misappropriating, or otherwise violating their intellectual property rights, the outcome of which would be uncertain and may prevent, delay or otherwise interfere with our product discovery and development efforts.
We may become involved in lawsuits to protect or enforce our patents, future patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful and could result in a finding that such patents are unenforceable or invalid.
Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment, and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
Changes in patent law in the United States and in non-U.S. jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our platform technologies and product candidates.
Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
If we do not obtain PTE and data exclusivity for any product candidates we may develop, our business may be materially harmed.
If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
Third parties have asserted and may in the future assert that we, our employees, consultants, or advisors have wrongfully used or disclosed confidential information or misappropriated trade secrets.
If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
Intellectual property rights do not necessarily address all potential threats.
If approved, our product candidates that are licensed and regulated as biologics may face competition from biosimilars approved through an abbreviated regulatory pathway.
Risks related to regulatory and other legal compliance matters
Regulatory requirements governing genetic medicines, and in particular any novel genetic medicines we may develop, have changed frequently and may continue to change in the future.
Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming, and uncertain and may prevent us from obtaining approvals for the commercialization of any product candidates we may develop. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize, or will be delayed in commercializing, product candidates we may develop, and our ability to generate revenue will be materially impaired.
Failure to obtain marketing approval in foreign jurisdictions would prevent any product candidates we may develop from being marketed in such jurisdictions, which, in turn, would materially impair our ability to generate revenue.
Any regulatory approval to market our products will be limited by indication. If we fail to comply or are found to be in violation of FDA regulations restricting the promotion of our products for unapproved uses, we could be subject to criminal penalties, substantial fines or other sanctions and damage awards.
Any product for which we obtain marketing approval in the future could be subject to post-marketing restrictions or withdrawal from the market and we may be subject to substantial penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with any such product following approval.
Fast track, breakthrough, or regenerative medicine advanced therapy designation by the FDA may not actually lead to a faster development or regulatory review or approval process and does not assure FDA approval of any product candidates we may develop.
Priority review designation by the FDA may not lead to a faster regulatory review or approval process and, in any event, does not assure FDA approval of any product candidates we may develop.
We may seek PRIME Designation in the EU for our product candidates, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.
We may seek designation for our platform technology as a designated platform technology, but we might not receive such designation, and even if we do, such designation may not lead to a faster regulatory review or approval process.
Inadequate funding for the FDA, the SEC and other government agencies, including from government shut downs, or other disruptions to these agencies’ operations, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
We may not be able to obtain orphan drug exclusivity for one or more of our product candidates, and even if we do, that exclusivity may not prevent the FDA or the EMA from approving other competing products.
Our relationships with healthcare providers, physicians, and third-party payors will be subject to applicable anti-kickback, fraud and abuse, anti-bribery and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, and diminished profits and future earnings.
Recently enacted and future legislation may increase the difficulty and cost for us and any future collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain.
The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our products, if and when licensed.
Our employees, principal investigators, consultants, and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
Laws and regulations governing international operations may preclude us from developing, manufacturing and selling certain product candidates outside of the United States and require us to develop and implement costly compliance programs.
Changes in and uncertainty surrounding U.S. and international trade policies may adversely impact our business and operating results.
We are subject to stringent privacy laws, information security laws, regulations, policies and contractual obligations related to data privacy and security and changes in such laws, regulations, policies and contractual obligations, and failure to comply with such requirements could subject us to significant fines and penalties and other consequences, which may have a material adverse effect on our business, financial condition or results of operations.
Social media platforms present new risks and challenges to our business.
Risks related to employee matters, managing growth and information technology
Our future growth may depend on our ability to identify and acquire businesses or technologies, and if we do not successfully do so, or otherwise fail to integrate any new businesses or technologies into our operations, we may have limited growth opportunities and it could result in significant impairment charges or other adverse financial consequences.
Our future success depends on our ability to retain our Chief Executive Officer, President and other key executives and to attract, retain, and motivate qualified personnel.
We expect to expand our development, regulatory, and future sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.
Risks related to our common stock
Legal proceedings
We are not currently a party to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities.
